Full 2009 ASCO Cancer & Oncology Primer (ABII, AEZS, ALTH, AMGN, APPA, ARQL, BMY, CLDX, CELG, CTIC, CGRB, LLY, EXEL, GHDX, GSK, IMGN, MEDX, MDVN, MITI, OGXI, OSIP, PPHM, PFE, ROSG, SNTA, TRBN, ZIOP, ZGEN)

May 27, 2009 · Filed Under Cancer, dendreon, R&D · Comments Off 

We have already seen a massive round of abstracts ahead of the huge American Society of Clinical Oncology, or ASCO meeting for 2009, which is scheduled to start this weekend.  ASCO is usually thought of as the Holy Grail of cancer conferences and these abstracts and presentations are viewed by investors, analysts, clinicians, doctors, and by cancer patients.

We compiled a brief synopsis for the following drug and biotech companies: Abraxis BioScience, Inc. (NASDAQ:ABII), AEterna Zentaris Inc. (NASDAQ: AEZS), Allos Therapeutics, Inc. (NASDAQ: ALTH), Amgen Inc. (NASDAQ: AMGN), A.P. Pharma, Inc. (Nasdaq: APPA), Arqule Inc. (NASDAQ: ARQL), Bristol-Myers Squibb (NYSE: BMY), Celldex Therapeutics (NASDAQ: CLDX), Celgene Corporation (NASDAQ: CELG), Cell Therapeutics (NASDAQ: CTIC), Cougar Biotechnology, Inc. (NASDAQ: CGRB), Eli Lilly and Company (NYSE: LLY), Exelixis (NASDAQ: EXEL), Genomic Health, Inc. (NASDAQ: GHDX), GlaxoSmithKline (NYSE: GSK) , Immunogen (NASDAQ: IMGN), Medarex (NASDAQ: MEDX), Medivation, Inc. (NASDAQ: MDVN), Micromet, Inc. (NASDAQ: MITI), OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), OSI Pharmaceuticals (NASDAQ: OSIP), Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), Pfizer Inc. (NYSE: PFE), Rosetta Genomics (NASDAQ:ROSG), Synta Pharmaceuticals (NASDAQ: SNTA), Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN), ZIOPHARM Oncology (NASDAQ: ZIOP), and ZymoGenetics, Inc. (NASDAQ: ZGEN).

Be advised that some of the data may have been changed since the first abstracts came out, but this is an expansive list of companies with data.
Read more

Many Laggards in Biotech Stocks Today (ACHN, CRXL, MNKD, SQNM, CYTR, CYTX, INGN, ATHX, MITI, GTOP)

June 10, 2008 · Filed Under General · Comments Off 

There have been many mystery movers today in biomed land and some are news carry-on moves while others are head-scratchers.  Out of the many names we follow in biotech, here are some losers as of 1:50 PM EST that stand out compared to the normal days:

Achillion Pharmaceuticals, Inc. (ACHN)    $2.45    Down $0.30    Down 10.91%
Additional ‘positive’ top-line phase 2 data for Elvucitabine

Crucell NV (CRXL)   $18.13    Down $0.64    Down 3.41%
No fresh news

MannKind Corp. (MNKD)    $2.7999    Down $0.1801    Down 6.04%
No fresh news besides tied to Novo’s news yesterday.

Sequenom Inc. (SQNM)    $12.17    Down $0.66    Down 5.14%
Sued yesterday by Beckman and partner Orchid.

CytRx Corporation (CYTR)    $0.7733    Down $0.0567    Down 6.83%
Drop on second day after Lou Gehrig’s drug delay.

Cytori Therapeutics, Inc. (CYTX)  $7.94    $Down 0.62    Down 7.24%
No fresh news today, post patent selling after big 2-day move.

Introgen Therapeutics Inc. (INGN)    $1.68    Down $0.09    Down 5.08%
No news, thin volume

Athersys, Inc. (ATHX)    $2.80    Down$ 0.29    Down 9.39%
No news yet out of diabetes and obesity conference, ahead of data but super thin volume

Micromet, Inc. (MITI)    $2.42    Down $0.20    Down 7.63%
No news, but presented non-Hodgkins data last week.

Genitope Corp. (GTOP)    $0.075    Down $0.013    Down 14.29%
Received NASDAQ letter on listing, but very low stock price so no surprise.

Jon Ogg
June 10, 2008

    Subscribe to BioHealth Investor BioHealth Investor RSS Feed